Allergic reactions have occasionally been seen, so it is recommended that the first dose of Dynepo be given under medical supervision.
The Committee for Medicinal products for Human Use (CHMP) decided that Dynepo's benefits are greater than its risks for the treatment of anaemia in patients with chronic renal failure.
Other information about Dynepo: The European Commission granted a marketing authorisation valid throughout the European Union, for Dynepo to Shire Pharmaceutical Contracts Ltd on 18 March 2002.
